What's the outlook for NVCR's EPS beyond 2025?

**NovoCure's EPS outlook beyond 2025 is uncertain and not currently available.** Here's an analysis based on available data:

1. **Current Financial Performance and Challenges**:
- NovoCure's recent financial results show a revenue increase of 21% year-over-year, reaching $161.3 million in Q4 2024, which matches analyst estimates. However, the company reported an EPS loss of $0.61 for the quarter, significantly worse than the estimated $0.34 loss due to heightened expenses.
- Despite the revenue growth, NovoCure's gross margin is under pressure, with a reported 79% gross margin in Q4 2024, which is a significant figure but does not provide a full picture of profitability.
2. **Analyst Expectations and Recent Performance**:
- Leerink Partners has raised its FY2025 EPS estimate for NovoCure to $1.40, up from the previous forecast of $1.42. This suggests a potential improvement in earnings outlook for the coming year.
- HC Wainwright has also boosted its FY2024 EPS estimates to $1.27, up from $1.35, and provided detailed quarterly estimates through FY2028. This indicates confidence in NovoCure's earnings trajectory, although the FY2024 estimate is slightly below the current consensus.
3. **Strategic Developments and Market Position**:
- NovoCure has achieved significant strides with FDA approvals and positive clinical trial outcomes, indicating potential for market expansion. The company's innovative cancer treatments using Tumor Treating Fields (TTFields) therapy could pave the way for future revenue growth.
- The company's market strategy focuses on advancing TTFields in tandem with traditional and emerging treatment methods, which could lead to sustained growth opportunities.
4. **Potential Challenges and Considerations**:
- While revenue growth is promising, the company's profitability is currently impacted by heightened expenses, which could affect EPS in the near term.
- The medical equipment industry's average growth forecast is 7.8%, compared to NovoCure's forecasted growth of 7.2% over the next three years. This suggests that while growth is expected, it may not outpace the industry average.

In conclusion, while there are positive indicators for NovoCure's future, including raised EPS estimates and strategic advancements, the exact EPS outlook beyond 2025 is not currently available. The company's ability to manage expenses and sustain revenue growth will be critical in determining its EPS trajectory.